KCSA Strategic Communications Advises Sensus Healthcare on Successful IPO: Rings the NASDAQ Bell Along Side Sensus Management

Press Release

June 10, 2016

New York, NY

KCSA Strategic Communications, a leading provider of integrated communications solutions announced its participation in the opening bell ringing ceremony at the Nasdaq MarketSite for its client, Sensus Healthcare, Inc. (NASDAQ: SRTSU), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids. With important employees, partners and families on hand, Sensus Healthcare Chief Executive Officer, Joseph Sardano, officially opened the trading day on Nasdaq. This ceremony comes on the heels of the successful Initial Public Offering (IPO) of Sensus Healthcare on Thursday, June 2, 2016. “The excitement we have when we are able to successfully advise one of our clients through the listing process on a major U.S. exchange such as Nasdaq is extremely gratifying,” commented Jeffrey Goldberger, Managing Partner, KCSA Strategic Communications. “For Sensus Healthcare, its IPO is the culmination of years of hard work and success. Having worked closely with management over the past few months to prepare for this moment is what we live for as investor relations consultants. We congratulate Joe Sardano and his team and look forward to working closely with the team to execute an investor relations program based on best practices.”
“Today’s listing on Nasdaq is a significant milestone for Sensus Healthcare. With decades of experience in the medical device industry, we launched Sensus with a simple goal – to provide medical professionals and their patients access to non-invasive options to treat non-melanoma skin cancer and keloids,” noted Joseph Sardano, Chief Executive Officer of Sensus Healthcare. “I am extremely proud of the entire Sensus team and wish to express my sincere gratitude for their tireless and continued support.” About KCSA Strategic Communications KCSA is a fully integrated communications agency specializing in public relations, investor relations and marketing with expertise in healthcare, technology and financial / professional services. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit About Sensus Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit SOURCE KCSA Worldwide Investor Relations: Kim Golodetz LHA Investor Relations Phone: 212-838-3777 Email:

Related Links

The Benefits of SRT

Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:

  1. 95%+ cure rates that rival surgery
  2. No anesthesia, cutting, bleeding, stitching or pain
  3. No downtime or lifestyle restrictions
  4. Super cosmesis, no unsightly scarring
  5. No need for post-treatment reconstructive surgeries